SummitTX Capital’s Akero Therapeutics AKRO Stock Holding History

SummitTX Capital’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,627	Closed	-$600K	–	684
2025 Q3	$600K	Sell	12,627 -5,845	-32%	-$283K	0.02%	487
2025 Q2	$986K	Sell	18,472 -12,086	-40%	-$549K	0.04%	378
2025 Q1	$1.24M	Buy	+30,558	New	+$1.3M	0.05%	348

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SummitTX Capital's AKRO Position: Q4 2025 in Review

SummitTX Capital sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 12,627 shares — an estimated $600K sold.

SummitTX Capital first reported a position in AKRO in Q1 2025 and held it in 3 quarters. The position peaked at $1.24M in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

SummitTX Capital reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
SummitTX Capital sold 12,627 Akero Therapeutics shares in Q4 2025, an estimated $600K.
SummitTX Capital first reported a position in Akero Therapeutics in Q1 2025 and held it in 3 quarters.
SummitTX Capital's Akero Therapeutics position peaked at $1.24M in Q1 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on SummitTX Capital's 13F filing for Q4 2025, filed 17 Feb 2026.